UK Expects…The AAR Innovation Review To Be More Than A Few Silver Bullets
This article was originally published in Clinica
Executive Summary
Enthusiasm surrounding the UK’s Accelerated Access Review (AAR), a program to speed innovative drugs, devices, diagnostics and digital products into usage in NHS England, was brought to a crescendo in early September. That was when AAR expert on medtech and external advisory group member John Jeans exhorted full participation in the online consultation on the AAR website.